Primary central nervous system lymphoma as a neurosurgical problem by Szczepanek, Dariusz et al.
Review article
Primary central nervous system lymphoma as a
neurosurgical problem
Dariusz Szczepanek a,*, Ewa Wąsik-Szczepanek b, Filip Stoma a,
Bożena Sokołowska b, Tomasz Trojanowski a
aDepartment of Neurosurgery and Paediatric Neurosurgery, Medical University in Lublin, Poland
bDepartment of Haematooncology and Bone Marrow Transplantation, Medical University in Lublin, Poland
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 1 ( 2 0 1 7 ) 3 1 9 – 3 2 3
a r t i c l e i n f o
Article history:
Received 2 February 2017
Accepted 10 April 2017
Available online 19 April 2017
Keywords:




a b s t r a c t
Primary central nervous system lymphoma (PCNSL) comprises around 3–5% of primary
central nervous system (CNS) tumours and around 1% of all non-Hodgkin lymphoma (NHL).
Diffuse large B-cell lymphoma (DLBCL) is the most common histological type. High effec-
tiveness of chemo- and radiotherapy for PCNSL regrettably does not eliminate signiﬁcant
risks of recurrence for CNS tumours. That results in higher interest in other treatment
options, including surgical procedures. PCNSL remains in the scope of interest for many
specialists and neurosurgeons seem to play a more important role.
© 2017 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Primary central nervous system lymphoma (PCNSL) is a rare
type of non-Hodgkin lymphoma (NHL). It comprises around 3–
5% of primary central nervous system (CNS) tumours and
around 1% of all NHL [1]. In more than 90% of cases it is diffuse
large B-cell lymphoma (DLBCL). T-cell lymphoma or those with
lower grade are far less common [2]. Histopathologically
PCNSL cannot be differentiated from the systemic form.
Signiﬁcant differences are estimated according to biological,
genetic and clinical aspects [3]. Acquired (AIDS) or congenital
immunodeﬁciency syndromes are established risk factors for
PCNSL. In case of severe congenital immunity disorders, such
as ataxia telangiectasia syndrome or Wiskott-Aldrich* Corresponding author at: Department of Neurosurgery and Paediatric
954 Lublin, Poland. Tel.: +48 81 7244 168.
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0028-3843/© 2017 Polish Neurological Society. Published by Elsevier Ssyndrome, the risk reaches around 4%. The frequency of
post-transplant lymphoproliferative disorders (PTLD) local-
ised in CNS after kidney, heart or lung transplantation is
estimated to be 1–7%. Infections with Epstein-Barr virus (EBV)
or iatrogenic T-lymphocyte dysfunctions play a key role in the
pathogenesis of these processes [3]. The answer to the
question on how lymphoma develops in areas normally free
from lymphoid tissue has not been clariﬁed so far. One of the
theories suggests ‘‘capturing’’ lymphocytes by CNS during an
inﬂammatory process and their further neoplastic transfor-
mation [4,5]. Lu et al. reported on a case of a 44-year-old female
patient who was diagnosed with PCNSL in the area where
active inﬂammatory process was detected 2.5 years previous-
ly. According to the authors, neuroinfection may precede or Neurosurgery, Medical University in Lublin, ul. Jaczewskiego 8, 20-
p. z o.o. All rights reserved.
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similar, especially in the initial stadium, which may lead to
diagnostic problems or make treatment difﬁcult. Inﬂammato-
ry processes usually cause demyelination or damage to the
nervous tissue, which differs considerably from PCNSL during
histological evaluation. That fact does not exclude hypotheses
which indicate the importance of inﬂammatory foci as the ﬁrst
‘‘immunological’’ response to developing tumours. However,
such suggestions need conﬁrmation in further studies [6].
Despite many controversies, chemo- and radiotherapy is the
most commonly recommended ﬁrst-line treatment for PCNSL.
Methotrexate (Mtx) is an important agent in monotherapy or in
conjunction with other cytostatic drugs. Both the range of dose
(1–8 g/m2) and its efﬁcacy are noticeable. Interestingly,
susceptibility to Mtx in PCNSL has been shown to be almost
three times higher than in systemic lymphoma [7].
2. Diagnostics
In patients with severe neurological symptoms, after perform-
ing computed tomography (CT) without contrast medium, a
hypodense lesion may be detected, which may resemble
ischaemic areas. Magnetic resonance imaging (MRI) is the
diagnostic tool to approximate the appropriate diagnosis.
PCNSL is iso-hypointensive in T1-weighted images and shows
hyperintensive signal in T2-weighted images. Administration
of contrast medium gives homogenous enhancement, how-
ever sometimes hypointensive necrosis is seen. In order to
differentiate other brain lesions [other primary or metastatic
tumours, neurosarcoidosis, infections] one should consider
extending diagnostics with positron emission tomography
(PET), single-photon emission computed tomography (SPECT),
MRI spectroscopy (MRS) or perfusion MRI [8]. These may
facilitate differentiation between PCNSL and glioma, which is
the most common CNS tumour in differential diagnosis. In the
case of PCNSL there is less damage of the blood–brain barrier,
more vascular permeability, lower central blood volume (CBV)
and higher leakage coefﬁcient when compared to glioma [9].
This information may be helpful to undertake the adequate
surgical strategy [biopsy/resection]. However the ﬁnal diagno-
sis of PCNSL requires histopathological evaluation of tissue
samples. Since collecting samples is repeatedly connected
with risk of complications, new alternative methods to reach
the speciﬁc diagnosis emerge. One of them is the examination
of cerebrospinal ﬂuid (CSF), whenever it is safe to perform a
lumbar puncture. Cytological, immunophenotype or genetical
evaluation is available. Detection of lymphoid cells in CSF
practically eliminates the necessity to perform biopsy [10].
However, it should be remembered that these cells are
detected only in 1/3 of cases and ‘‘negative’’ results of CSF
examination do not rule out PCNSL. Reports on evaluation of
miRNA [non-coding RNA molecules, regulating other gene
expressions] from CSF have shown lately. In particular, they
concern miR-21, mir-19b and miR-92a, whose speciﬁcity for
PCNSL reached 96.7% [11].
In order to conﬁrm the primary lymphoma location in CNS,
complex examination of the patient should be performed. It
consists of full blood count, blood biochemistry [kidney and
liver function tests, LDH concentration] and serology (HIV), fulleye examination, CSF evaluation. The following are required:
brain MRI; CT of neck, chest, abdomen and pelvis; bilateral
trepanobiopsy. Testicular ultrasound examination is recom-
mended, especially in older men and in younger men
whenever there are abnormalities in physical examination.
3. Steroid therapy
Immunosuppressive and cytostatic effect of corticosteroids on
neoplastic cells is used in treating lymphoma. Their role is
shown to be essential in the case of PCNSL, however many
controversies of their application are emphasised. First effects
are usually present after 2–3 days (dexamethasone 8–32 mg/
day) and mainly involve oedema reduction, which gives
temporary neurological stability. Uncommonly observed
complete response (CR) or partial response (PR) of lymphoma
lesion may appear as soon as within a few hours. However, it is
most commonly expected after at least 10 days. The percent-
age of patients with a possible reaction of this type is
estimated to be 15% and 25%, respectively [12]. Discontinua-
tion of corticosteroid therapy is always connected with a real
and extremely possible risk of recurrence at different times.
One of the longest remission periods [6.5 years] was reported
by Herrlinger et al. [13]. Unfortunately, resumption of
treatment does not guarantee success. The maintenance of
obtained partial or complete remission is not possible even
with permanent corticosteroid therapy. No response to
treatment or its considerable reduction results from a few
reasons. One of them may be clonal evolution of lymphoid
cells, resistant to the drug effect. This resistance may result
from both low expression of glucocorticoid receptors [14] and
high expression of gene bcl-2 – responsible for apoptosis
processes [15]. Önder et al. reported on interesting results
when evaluating the inﬂuence of pre-therapy with corticoste-
roids on histopathological results of stereotactic biopsy
samples in PCNSL patients. It turned out that reaching the
diagnosis was trouble-free only in less than half patients (48%).
However, atypical changes of lymphoid cells were detected in
all the other cases, which caused problems in reaching the
adequate diagnosis [16]. Histopathological pictures may
sometimes suggest an inﬂammatory process. Areas of
demyelination and T-cell inﬁltrations are occasionally ob-
served [17]. Thus Patrick et al. suggest discontinuation of
corticosteroids 7–10 days prior to elective biopsy [18]. Cortico-
steroids are also reported to have an unfavourable effect
during administration of cytostatic drugs by ‘‘tightening’’ the
blood–brain barrier. In that manner they are thought to
decrease penetration of cytostatic drugs to the brain tissue
[17]. On the other hand however, some researchers report on
potential prognostic importance of the initial reaction to
steroids. A retrospective analysis of 57 PCNSL patients proved
that regression of radiological lesions and clinical improve-
ment have a signiﬁcantly beneﬁcial inﬂuence on overall
survival [19]. Adequate ‘‘radiological’’ response to corticoster-
oid therapy together with MRI and FDG-PET, according to
Yamaguchi et al., may be used as an alternative method to
diagnose PCNSL. It involves lesions located in deep brain
structures, for which surgical treatment is connected with
high risk of complications [20].
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Cerebrospinal ﬂuid is probably a speciﬁc reservoir of lymphoid
cells in some PCNSL patients. Therefore, intraventricular or
intrathecal injections of cytostatic drugs combined with
systemic chemotherapy are commonly placed in many
therapy protocols. It is possible thanks to an Ommaya
reservoir which may be implanted already during stereotactic
biopsy [21]. One of the well-known regimens is Boston
multidrug regimen used by Pels et al. in 65 PCNSL patients.
The authors reported on high 71% response rate (61% CR and
10% PR). Overall median survival (OS) was 34 months for
patients older than 60 years and was not reached for younger
patients. Infectious complications were observed in 19% cases.
Their presence is explained by immunodeﬁciencies due to
steroid therapy and myelosuppression due to cytostatic drugs.
Also frequent (according to the protocol) administration of
drugs via the reservoir plays an important role [22]. Rubinstein
et al. in the ﬁrst prospective phase I trial evaluated the efﬁcacy
and safety of intraventricular immunochemotherapy with
rituximab and methotrexate in patients with recurrent or
drug-resistant PCNSL. This trial was the answer to search for
new treatment modalities of this highly selected group of
patients with an extremely unfavourable prognosis. In 75% of
patients complete eradication of lymphoid cells form CSF was
observed, and in 43% it also involved the brain. Regression of
lymphoma lesions was noted in corpus callosum and basal
ganglia, which were the structures previously thought to be
hard to reach for cytostatic drugs dissolved in CSF. The authors
also suggest that concomitant administration of rituximab
with Mtx delays elimination of rituximab from CSF. A short
half-life of monoclonal antibody is thought to be one of the
main reasons for resistance to intraventricular rituximab
injections [which usually appears after 1–3 months of
treatment]. This probably leads to evolution of drug-resistant
clone of lymphoid cells [23].
Rituximab is a murine/human chimeric anti-CD20 mono-
clonal antibody, speciﬁc for B cell line. It shows high activity
in treating systemic diffuse large B-cell lymphoma [24].
However, the concentration of rituximab in CSF reaches only
around 1% of its serum concentration after intravenous
injection [25]. A reasonable explanation for occasional usage
of this antibody in induction therapy for PCNSL is a severe
damage of the blood–brain barrier in the initial phase of the
disease [26].
5. Stereotactic radiosurgery
Primary lymphoma of CNS is characteristic for its high
susceptibility to radiotherapy. Ever since its ﬁrst introduction
in early sixties, mainly as the whole-brain radiation therapy
[WBRT], it has been a permanent element of many therapeutic
protocols. Currently it is known that when applied alone WBRT
has many limitations which result from its inadequate efﬁcacy
[overall median survival was a little more than 11 months,
with recurrent disease in the ﬁeld of radiation in more than
half of patients] [27] and from longterm harmful effects of
radiation. Even though their character is known, themechanism of neurotoxicity is still questionable. Possible
explanations include oxidative stress, oligodendrocyte dam-
age, neurocyte stem cell damage, demyelination or vasculo-
pathy [28]. At the same time it is known that CNS damage
degree depends mainly on cumulative total radiation dose [29].
Stereotactic radiosurgery (SRS) is a surgical technique which
uses a single, localised, high dose of ionising radiation, with a
maximal protection of healthy tissues [30]. According to many
authors, SRS has many advantages. Among them is the
possibility to perform it in a short period of time [usually one
day] and to repeat it when needed. It gives an opportunity to
apply a high dose of radiation in locations which are
inaccessible for neurosurgery. SRS is not in conﬂict with
systemic chemotherapy, and sometimes it may be the only
alternative form of treatment in patients who may not be
treated with cytostatic drugs due to multi-organ damages [31].
The idea of applying SRS was presented in a few retrospective
studies. The attempts involved both primary and recurrent
PCNSL. Sakamoto et al. presented results of treatment in 9
patients who were diagnosed with recurrent CNS lymphoma
(both single and multiple neoplastic lesions). All of them
underwent WBRT before. The percentage of response (CR + PR)
was 87%. Overall median survival and progression free
survival (PFS) was 7.7 and 3.7 months, respectively. At the
same time it has been proven that OS is signiﬁcantly longer
with prior application of systemic chemotherapy in compari-
son to patients with no cytostatic treatment (median 5.9 vs.
13.0 months) [32]. Kenai et al. treated a signiﬁcantly larger
group of 22 patients. Altogether 48, mainly recurrent,
lymphoma lesions were treated with Gamma Knife Surgery
(GKS), which resulted in signiﬁcant reduction or complete
regression of lesions. The authors emphasised high efﬁcacy
[100% response] and safety of the therapy. They did not
observe progression or recurrence of lymphoma in the primary
site over the mean period of 19.4 months. Newly appearing
neoplastic foci still reacted well to GKS. Median OS was 38
months [33]. Studies carried out by Hirono et al. have an
innovative character, since they attempt to combine SRS with
high-dose methotrexate (HD-Mtx) as ﬁrst-line therapy in
patients with newly diagnosed PCNSL. SRS was supposed to
replace WBRT in this case and to complement the activity of
HD-Mtx at the same time. From 51 patients, radiosurgery was
ﬁnally applied in 20 people due to residual or recurrent
lymphoma changes. Median OS was 52 months with no
signiﬁcant adverse effects [34]. The role of SRS in treating
PCNSL is a subject of many discussions. However, it is not
questionable for other recurrent brain tumours, such as
gliomas, meningiomas or metastatic tumours [35–38]. Its
efﬁcacy evaluated in the aspect of overall survival depends
on many factors. Some of the particularly include the radiation
dose and clinical status of patients before treatment, described
by Karnofsky scale. It also seems that SRS is a therapeutic
modality for which ‘‘local control’’ of lymphoma lesions is the
main goal [39].
6. Surgical treatment
Despite high efﬁcacy of chemo- and radiotherapy in PCNSL,
there is a signiﬁcant risk of recurrence for neoplastic CNS
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options, including surgical management. Theoretical
assumptions which justify this type of approach point to
the possibility of cytoreductive effect and elimination of
genetically unstable lymphoid cells that are resistant to
cytostatic treatment [40]. One of the core arguments against
radical surgical actions is the fact that lymphoma changes in
CNS are repeatedly multifocal and practically spread
throughout the whole brain. Some authors also suggest
the possibility of migration of lymphoid cells to the
subarachnoid space during the procedure [41]. Since [accord-
ing to autopsy studies] lymphoma has no capsule, cases of
recurrent CNS lymphoma in areas remote to the primary site
were observed [42]. Many scientiﬁc papers and protocols of
national and international neurosurgical bodies questioned
the efﬁcacy of lymphoma resection. Emerging reports did not
change those opinions. Sonstein et al. described 5-year
overall survival in a PCNSL patient after gross total resection
of the lesion and short lasting steroid therapy [43]. Trapella
et al. reported on more-than-79-month OS. Radio- and
chemotherapy was applied in their patient after gross total
tumour resection [44]. Davis et al. presented however the
most spectacular case (more-than-twenty-year overall sur-
vival) [45]. In a large report Bataille et al. showed results of
retrospective studies on 248 PCNSL patients, where one-year
overall survival was 56.6% for those after gross total
resection, 31.8% for those after non-total resection and
48.6% in those after biopsy [46]. The revision of previous
sceptical opinions is based on the results gathered in a
randomised phase III study, conducted by the German group
G-PCNSL-SG-1, which evaluated the efﬁcacy of WBRT in 526
patients with newly diagnosed PCNSL. One of fairly unex-
pected (and not included in the study hypotheses) conclu-
sions was longer overall survival and progression free time in
the group after gross total or non-total tumour resection in
comparison to the patients after biopsy only. At the same
time, no signiﬁcant correlation between the location of
lymphoma and OS or PFS was proven. The study may provide
the basis for changing the acknowledged standpoint that the
scope of neurosurgical procedures has no prognostic value,
and – what is more – it may simply suggest that gross total or
non-total tumour resection (especially in the case of single
tumours) may result in measureable beneﬁts for the patient
(providing it does not generate the risk of neurological
complications or does not postpone further chemotherapy).
Due to the signiﬁcance of the problem, attempts to deﬁne the
ﬁnal importance of scopes of neurosurgical procedures seem
to be necessary in prospective clinical trials [47].
7. Summary
Primary central nervous system lymphoma is a problem which
requires involvement of different specialists (neurosurgeon,
neurologist, histopathologist, haematologist, oncologist).
Their good and adequate cooperation results in the ﬁnal
success with improvement of yet not fully satisfying treatment
effects. The role of neurosurgeon seems to may have an even
greater importance in this process. However, it requires
further intensive studies.Conﬂict of interest
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